2nd ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers
15 ESCO credits
02.12.2017 - 04.12.2017
Milan, Italy
COURSES AND SEMINARS
Description
Chairs: J.Y. Blay, FR - P.G. Casali, IT - R. Stahel, CH
Rare cancers make up as many as one fifth of all new cancer cases. Amongst them, pediatric cancers and rare hematologic neoplasms are often covered by dedicated educational events, while rare adult solid cancers are hardly grouped together and approached as a collective group of neoplasms. Indeed, they account for as many as 15% of all new cancer cases, thus being the main group within rare cancers. This Course is aimed at dealing with them on an annual basis, to provide the community of clinical oncologists specialising in these tumors with a regular update of recent advances in this specific area. The ultimate goal is to strengthen the educational coverage of a group of cancers which may be neglected in spite of their collective incidence.
According to the RARECARE project, which provided a definition and a list of rare cancers, rare adult solid cancers include the following big families of tumors, each of them being therefore covered by a corresponding educational session within this Course:
• Rare skin cancers & non-cutaneous melanoma
• Rare thoracic tumors
• Rare female genital cancers
• Neuroendocrine tumors
• Endocrine gland tumors
• Sarcomas
• Digestive rare cancers
• Rare urological and male genital tumors
•Central nervous system neoplasms
• Head & neck cancers
Any educational effort in the rare cancer area makes little sense if disconnected from a networking environment.
This year we are amid the process of creation of the new European Reference Networks (ERN) on rare diseases, including rare adult solid cancers, with the ERN named EURACAN. Many speakers and moderators will thus come from EURACAN and definitely will be happy to meet Oncologists working within it or in collaboration with it.
From the educational point of view, one cannot expect that even experienced clinical oncologists are knowledgeable about all these tumours. For this reason, the European Faculty of this Course is asked to focus on most recent advances always trying to put them into the context of state-of-the-art treatment of these tumors, with a special view to ESMO Clinical Practice Guidelines.
LEARNING OBJECTIVES
• Update on the latest clinical development on RC’s with a background perspective on the state-of-the-art approach
Rare cancers make up as many as one fifth of all new cancer cases. Amongst them, pediatric cancers and rare hematologic neoplasms are often covered by dedicated educational events, while rare adult solid cancers are hardly grouped together and approached as a collective group of neoplasms. Indeed, they account for as many as 15% of all new cancer cases, thus being the main group within rare cancers. This Course is aimed at dealing with them on an annual basis, to provide the community of clinical oncologists specialising in these tumors with a regular update of recent advances in this specific area. The ultimate goal is to strengthen the educational coverage of a group of cancers which may be neglected in spite of their collective incidence.
According to the RARECARE project, which provided a definition and a list of rare cancers, rare adult solid cancers include the following big families of tumors, each of them being therefore covered by a corresponding educational session within this Course:
• Rare skin cancers & non-cutaneous melanoma
• Rare thoracic tumors
• Rare female genital cancers
• Neuroendocrine tumors
• Endocrine gland tumors
• Sarcomas
• Digestive rare cancers
• Rare urological and male genital tumors
•Central nervous system neoplasms
• Head & neck cancers
Any educational effort in the rare cancer area makes little sense if disconnected from a networking environment.
This year we are amid the process of creation of the new European Reference Networks (ERN) on rare diseases, including rare adult solid cancers, with the ERN named EURACAN. Many speakers and moderators will thus come from EURACAN and definitely will be happy to meet Oncologists working within it or in collaboration with it.
From the educational point of view, one cannot expect that even experienced clinical oncologists are knowledgeable about all these tumours. For this reason, the European Faculty of this Course is asked to focus on most recent advances always trying to put them into the context of state-of-the-art treatment of these tumors, with a special view to ESMO Clinical Practice Guidelines.
LEARNING OBJECTIVES
• Update on the latest clinical development on RC’s with a background perspective on the state-of-the-art approach
| The course is an ESO-ESMO-RCE joint event | ||||||||||
 |  | |||||||||
| Held in collaboration with | In the framework of | |||||||||
 |  |  | ||||||||
| A Pilot Training Course for Rare Cancer Patient Advocates will run in parallel. | ||||||||||
General information
ORGANISING SECRETARIAT
European School of Oncology
Rare Tumours Programme
c/o Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1
20133 Milano - Italy
Fax +39 0223902531
Email: raretumours@eso.net
VENUE
Fondazione Cariplo Conference Center
Via Romagnosi, 8
Milan
www.centrocongressifondazionecariplo.it
ACCREDITATION
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.
The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 14 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Furthermore, the event has been designed for 12,5 Italian CME credits.
BADGE
The badge is the only official evidence of registration and should be worn at all times during the event.
INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the Course. Participants are advised to take out their own personal and travel insurance.
OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.
TRAVEL GRANTS
Travel grants were made available on a competitive basis thanks to the support of Rare Cancers Europe. Priority was given to younger candidates and low/middle income Countries.
The applicationd deadline has passed (1 October 2017).
All applicants will be contacted by 15th October. Unselected applicants will still be able to register with the early rate fee (deadline: 31st October).
| Participants coming from: | ||
| Italy | EUR 500 (plus free registration) | |
| Southern and Western Europe | EUR 700 (plus free registration) | |
| Northern, Central and Eastern Europe | EUR 800 (plus free registration) | |
| Other and overseas | EUR 1000 (plus free registration) |
ACKNOWLEDGEMENT
ESO wishes to express its gratitude to Fondazione Cariplo - Iniziative Patrimoniali S.p.A. for their support in hosting the course in its premises.
 |
and to Bristol-Myers Squibb, Lilly Oncology, Merck and PharmaMar for their unrestricted educational grants.
 |  |  |  | ||||||||
Faculty list
FACULTY
M. Angi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
S. Bielack, Klinikum Stuttgart Olgahospital, Stuttgart, DE
J.Y Blay, Centre Léon Bérard, Lyon, FR
P.G. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. De Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A.P. Dei Tos, Azienda ULSS9, Treviso, IT
C. de la Fouchardière, Centre Léon Bérard, Lyon, FR
De Lorenzo, European Cancer Patient Coalition, Brussels, BE
M. Deraco, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
N. Fazio, Istituto Europeo di Oncologia, Milan, IT
S. Ferrari, Istituti Ortopedici Rizzoli, Bologna, IT
A.M. Frezza, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Garassino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
J.A. Gietema, University Medical Center, Groningen, NL
R. Glynne-Jones, Mount Vernon Centre for Cancer Treatment, London, UK
V. Gregoire, Universitè Catholique, Louvain, BE
S. Grisanti, A.O. Spedali Civili, Brescia, IT
A. Gronchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
C. Lebbé, Hopital St. Louis, Paris, FR
S. Leboulleux, Institut Gustave Roussy, Villejuif, FR
L. Licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
D. Lorusso, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
V. Mazzaferro, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A. Necchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
N. Nicolai, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
K. Oliver, International Brain Tumour Alliance, Tadworth, UK
F. Peccatori, European School of Oncology, Milan, IT
C. Piazza, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
G. Pravettoni, Istituto Europeo di Oncologia, Milan, IT
F. Raspagliesi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR
M. Seckl, Hammersmith Campus, London, UK
C. Simon, Université de Lausanne, CHUV Lausanne, CH
R. Soffietti, AOU San Giovanni Battista, Torino, IT
S. Stacchiotti, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
R.A. Stahel, Cancer Center University Hospital, Zurich, CH
D. Talbot, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
J.C. Tonn, University of Munich, Munich, DE
A. Trama, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Van den Bent, Erasmus MC Cancer Institute, Rotterdam, NL
S. Villà, Hospital Universitari Germans Trias i Pujol, Badalona, ES
L. Wyrwicz, Curie Institute of Oncology, Warsaw, PL
Programme
DECEMBER 2
| 9:00 | Registration and coffee entry | |
| INTRODUCTION (Plenary session*) Moderators: J.Y. Blay FR - PG Casali IT - R Stahel CH | ||
| 9:45 | Welcome from ESO and ESMO F. Peccatori, IT - R.A. Stahel, CH | |
| 10:00 | The problem of rare cancers P.G. Casali IT | |
| 10:15 | The epidemiology of rare cancers A. Trama, IT | |
| 10:30 | The pathologic diagnosis in rare cancers A.P. Dei Tos, IT | |
| 10:45 | The European Reference Networks J.Y. Blay, FR | |
| 11:00 | Discussion | |
| PATIENT EMPOWERMENT IN RARE CANCERS (Plenary session *) Moderators: F. De Lorenzo, BE - K. Oliver, UK | ||
| 11:30 | Patient empowerment in rare cancers: a consensus G. Pravettoni, IT | |
| 11:50 | The EU scenario F. De Lorenzo, BE | |
| 12:10 | Patients & Experts: The power of working together K. Oliver, UK | |
| 12:30 | Discussion | |
| 13:00 | Lunch | |
| RARE THORACIC CANCERS Moderators: M. Garassino, IT - RA Stahel, CH | ||
| 14:00 | The epidemiology of mesothelioma A. Trama, IT | |
| 14:15 | Mesothelioma R.A. Stahel, CH | |
| 14:30 | Thymic tumors M. Garassino, IT | |
| 14:45 | Discussion | |
| NEUROENDOCRINE TUMORS Moderators: D. Talbot, UK - F. De Braud, IT | ||
| 15:15 | Thoracic neuroendocrine tumors D. Talbot, UK | |
| 15:30 | Gastroenteropancreatic neuroendocrine tumors N. Fazio, IT | |
| 15:45 | Surgery in neuroendocrine tumors V. Mazzaferro, IT | |
| 16:00 | Discussion | |
| 16:30 | Coffee break | |
| DIGESTIVE RARE CANCERS Moderators: V. Mazzaferro, IT - L. Wyrwicz, PL | ||
| 17:00 | Biliary tumors F. De Braud, IT | |
| 17:15 | Anal carcinoma R. Glynne-Jones, UK | |
| 17:30 | Peritoneal mesothelioma & pseudomyxoma M. Deraco, IT | |
| 17:45 | Discussion | |
DECEMBER 3
| CNS TUMORS Moderators: R. Soffietti, IT - M. van den Bent, NL | ||
| 08:30 | The frontiers of neurosurgery of brain tumors J.C. Tonn, DE | |
| 8:45 | The frontiers of radiation therapy of brain tumors S. Villà, ES | |
| 9:00 | Gliomas: state-of-the-art approach M. van den Bent, NL | |
| 9:15 | Precision medicine in brain tumors R. Soffietti, IT | |
| 9:30 | Discussion | |
| 10:00 | Coffee break | |
| SARCOMAS Moderators: P.G. Casali IT - A Gronchi IT | ||
| 10:30 | The variegated pathology of sarcomas A.P. Dei Tos, IT | |
| 10:45 | The surgical margin in sarcomas A. Gronchi, IT | |
| 11:00 | Medical therapy of adult soft tissue sarcomas P.G. Casali, IT | |
| 11:15 | Medical therapy of GIST J.Y. Blay, FR | |
| 11:30 | Ewing sarcoma S. Ferrari, IT | |
| 11:45 | Osteosarcoma S. Bielack, DE | |
| 12:00 | “Rare” sarcomas S. Stacchiotti, IT | |
| 12:15 | Histiocytic/dendritic cell neoplasms A.M. Frezza, IT | |
| 12:30 | Discussion | |
| 13:00 | Lunch | |
| RARE FEMALE GENITAL CANCERS Moderators: F. Raspagliesi, IT - M. Seckl, UK | ||
| 14:00 | Vulvar and vaginal cancers F. Raspagliesi, IT | |
| 14:15 | Rare endometrial cancers D Lorusso, IT | |
| 14:30 | Uterine sarcomas P.G. Casali, IT | |
| 14:45 | Non-epithelial ovarian tumors I. Ray-Coquard, FR | |
| 15:00 | Trophoblastic tumors M Seckl, UK | |
| 15:15 | Discussion | |
| 15:45 | Coffee break | |
| RARE UROGENITAL CANCERS Moderators: J.A. Gietema, NL - N. Nicolai, IT | ||
| 16:15 | Testicular cancer A. Necchi, IT | |
| 16:30 | Penile cancers J.A. Gietema, NL | |
| 16:45 | Discussion | |
| RARE SKIN TUMORS & UVEAL MELANOMA Moderators: M. Angi, IT - C. Lebbé, FR | ||
| 17:15 | The integrated approach to uveal melanoma M. Angi, IT | |
| 17:30 | Merkel cell carcinoma C. Lebbé, FR | |
| 17:45 | Skin adnexal tumors L. Licitra, IT | |
| 18:00 | Discussion | |
DECEMBER 4
| HEAD & NECK CANCERS Moderators: V. Gregoire BE - L. Licitra, IT | ||
| 8:30 | Natural history of H&N cancers C. Simon, CH | |
| 8:45 | The potential of radiation therapy for H&N cancers V. Gregoire, BE | |
| 9:00 | Surgery in H&N cancers and its innovations C. Piazza, IT | |
| 9:15 | Laryngeal & hypopharyngeal carcinoma L. Licitra, IT | |
| 9:30 | Oropharyngeal carcinoma V. Gregoire, BE | |
| 9:45 | Nasopharyngeal carcinoma L. Licitra, IT | |
| 10:00 | Oral cavity tumors C. Simon, CH | |
| 10:15 | Salivary gland tumors L. Licitra, IT | |
| 10:30 | Discussion | |
| 11:00 | Coffee break | |
| ENDOCRINE GLAND TUMORS Moderators: S. Leboulleux FR - L. Licitra IT | ||
| 11:30 | Adrenal cancer S. Grisanti, IT | |
| 11:45 | Thyroid cancer S. Leboulleux, FR | |
| 12:00 | Anaplastic thyroid carcinoma C. De La Fouchardière, FR | |
| 12:15 | Discussion | |
| 12:45 | Closing remarks, with a view to networking… P.G. Casali, IT (Plenary *) | |
| * Linked to Rare Cancer Patient Advocates pilot training course | ||
Resources
RCE-ESO-ESMO Rare Cancers training course for Patient Advocates December 2017
Oncology Meeting Resources
02 Dec - 04 Dec 2017, Milan, Italy
From the 2nd to 4th of December 2017, RCE organised a specific training course for rare cancers patient advocates. The event brought together patient advocates from across Europe, including Turkey and Russia, who could exchange views and ideas with clinicians and researchers, who were attending the ESO-ESMO-RCE Clinical Update on Rare Cancers event in the same building and to learn about crucial points of rare cancers advocacy.
Further information can be obtained here.